About Us

Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

A Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Social Media

Bluesky • Facebook • Instagram • LinkedIn • YouTube

Meet the Laser Focus World Team

Editorial

Sales

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology
My Watchlist
Indicators
Industrial Laser Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Indivi and Clouds of Care Partner to Advance Deep Phenotyping in Early Alzheimer’s and Parkinson’s Drug Development

By: via Business Wire

Indivi and Clouds of Care, two independent TechBio companies, today announced a strategic partnership to advance the use of precision medicine tools in early-phase neuroscience drug development, targeting Alzheimer’s and Parkinson’s disease.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251015326876/en/

The field of neurodegeneration remains one of the toughest challenges in medicine, with a historically low probability of technical and regulatory success (PTRS). The highest attrition occurs between First-in-Human and Proof-of-Concept studies, where conventional endpoints lack the sensitivity needed to detect early treatment effects.

“Age being the principal risk factor for neurodegenerative diseases, we are facing a global pandemic,” says Michel Vounatsos, Chair of the Board of Directors of Clouds of Care. “Deep phenotyping technologies will be essential to improve drug development success in Alzheimer’s and Parkinson’s Disease and extend healthy brain ageing across the lifespan.”

The partnership will integrate world-class expertise in neuro-electrophysiology (resting-state EEG, event-related potentials, and polysomnography) with digital health technology tools. Together, they aim to establish a unified R&D framework for multimodal deep phenotyping, combining biological (electrophysiology-based) and functional (cognitive and motor behavior) measures to deliver earlier, more definitive Proof-of-Biology (PoB) and Proof-of-Concept (PoC) signals in early drug development trials.

This collaboration creates a technology-integrated value proposition, which de-risks early clinical development, by increasing the signal-to-noise ratio of PoB-PoC endpoints, thereby enhancing the PTRS, and potentially improving the risk-adjusted Net Present Value (rNPV) and accelerating time-to-market for biopharmaceutical partners.

The initiative aligns with the European Medicines Agency’s (EMA) recent call for updated guidelines on early Alzheimer’s trials, emphasizing the need for more responsive and clinically meaningful endpoints in early clinical phases.

“It is not just about bringing deep phenotyping technologies together,” says Shibeshih Mitiku Belachew, Chief Medical Officer of Indivi. “It is about creating a true symbiosis between clinical development and the science of enabling technologies to design smarter, faster, and more successful trials.”

About Indivi & Deep Phenotyping Measures of Cognitive and Motor Functions for Proof-of-Concept Demonstration of Disease Modification:

Indivi is an ISO 13485 and ISO 27001-certified TechBio company headquartered in Basel (CH) and developing future-proof functional biomarkers derived from Digital Health Technology (DHT) tools measuring key disability concepts of importance (motion and cognition) for drug development trials in neuroscience.

  • Indivi developed the most comprehensive suite of smartphone-based assessments (N=20) of motor and cognitive functions, including Konectom1,2, a digital biomarker platform in-licensed from Biogen in 2024.
  • CoGames3 is a proprietary battery of smartphone-based gamified and user-adaptive cognitive assessments (ACA).
  • CoGames entails a unique system of dynamic difficulty adaptation to individual performance, which enables personalizing the difficulty of each cognitive assessment for each subject, at trial baseline.
  • Publications : https://indivi.io/insights

About Clouds of Care & Deep Phenotyping Measures of Brain Activity for Proof-of-Biology Demonstration of Disease Modification:

Clouds of Care NV is an ISO 13485 and ISO 27001-certified TechBio company in Ghent, Belgium, housing CE-marked and FDA-cleared electrophysiology applications for clinicians and tailor-made clinical development solutions for biopharmaceutical companies. Through its comprehensive CNS platform and strategic network of partners, Clouds of Care is revolutionizing care for people with Central Nervous System disorders.

  • Resting-state EEG during wakefulness and sleep measures direct and indirect effects of active compounds on brain activity as a pharmaco-dynamic readout of therapeutic response at the level of neuronal biology.
  • Event-related potentials (ERPs), recorded using scalp EEG, offer a non-invasive, high-temporal-resolution method for assessing cognitive and socio-emotional activity of neurons in response to sensory and cognitive stimuli. ERPs enable the quantification of biological dysfunctions in information processing, even in minimally communicative patients. Sensitivity to subtle neural changes makes ERPs valuable PoB endpoints for early-stage clinical trials.
  • The proprietary Electrical Source Imaging (ESI) of Clouds of Care estimates the 3D spatial distribution of the brain activity source localization (using an electromagnetic model built from the subject-level brain MRI), which is essential to capture spatially heterogeneous disease signatures as those observed in Alzheimer’s and Parkinson’s diseases.
  • Publications : https://www.cloudsofcare.com/publications

____________________

1 https://konectom.com

2 Llorens-Arenas R et al. Smartphone-based digital assessments in the LUMA trial of BIIB122/DNL151 for early-stage Parkinson’s disease. International Congress of Parkinson’s Disease and Movement Disorders, 2025, Poster P860, October 7, Hawaii, USA

3 Rodríguez-Romero A et al. Biomarkers of Alzheimer’s disease modification using adaptive cognitive assessments to improve responsiveness - a simulation study. Front. Neurosci. 2025, 19:1653261.

 

Contacts

More News

View More
Advanced Micro Devices Eyes $300 as AI Demand Surges
Via MarketBeat
Topics Artificial Intelligence
Tickers AMD AMZN GOOGL MSFT NVDA ORCL
Qualcomm: What Last Friday’s Drop Says About Its Q4 Prospects
Via MarketBeat
Tickers AMD NVDA QCOM
3 Rare Earth Stocks Powering America’s Critical Minerals Boom
Via MarketBeat
Topics Artificial Intelligence Economy
Tickers CRML LAC MP
Why Analysts Are Upgrading Ratings After Klarna's IPO
Via MarketBeat
Topics Initial Public Offering
Tickers AFRM BAC GAP JPM KLAR WMT
Palantir’s New Healthcare Deal Boosts AI and Data Reach
Via MarketBeat
Topics Artificial Intelligence
Tickers ONMD PLTR
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.